Immix Biopharma (NASDAQ:IMMX) Given New $15.00 Price Target at HC Wainwright

Immix Biopharma (NASDAQ:IMMX) had its price target boosted by research analysts at HC Wainwright from $12.00 to $15.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 72.02% from the company’s current price.

A number of other brokerages have also recently issued reports on IMMX. Wall Street Zen cut Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Mizuho assumed coverage on shares of Immix Biopharma in a research report on Monday, February 9th. They set an “outperform” rating and a $14.00 target price for the company. Morgan Stanley initiated coverage on shares of Immix Biopharma in a report on Wednesday. They set an “overweight” rating and a $20.00 price target for the company. Finally, Citizens Jmp assumed coverage on shares of Immix Biopharma in a research report on Monday, March 9th. They issued an “outperform” rating and a $23.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Immix Biopharma Price Performance

Shares of IMMX stock opened at $8.72 on Friday. The stock’s fifty day simple moving average is $7.70 and its 200 day simple moving average is $5.20. The firm has a market cap of $461.81 million, a price-to-earnings ratio of -9.80 and a beta of 0.25. Immix Biopharma has a one year low of $1.34 and a one year high of $11.61.

Institutional Trading of Immix Biopharma

Several large investors have recently made changes to their positions in the business. Allworth Financial LP acquired a new stake in shares of Immix Biopharma in the fourth quarter valued at $30,000. Velan Capital Investment Management LP acquired a new position in Immix Biopharma during the 2nd quarter worth about $52,000. Mathes Company Inc. bought a new stake in Immix Biopharma during the 4th quarter worth about $56,000. Balyasny Asset Management L.P. bought a new stake in Immix Biopharma during the 4th quarter worth about $67,000. Finally, Kera Capital Partners Inc. acquired a new stake in Immix Biopharma in the 4th quarter valued at about $68,000. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.